ENHANZE Drug Delivery Technology : Advancing Subcutaneous Drug Delivery using Recombinant Human Hyaluronidase PH20

ENHANZE drug delivery technology: Advancing subcutaneous drug delivery using recombinant human hyaluronidase PH20' provides readers with in-depth information on the potential benefits and challenges of subcutaneous (SC) drug delivery, the biology of hyaluronan and hyaluronidases in the SC space, and a comprehensive overview on the history of hyaluronidases and the development of recombinant human hyaluronidase PH20 (rHuPH20). Current applications of rHuPH20 as well as approved biotherapeutics utilizing HuPH20-facilitated SC drug delivery are summarized, and the underlying non-clinical and clinical development approaches are introduced as a basis for future application to biologics in various disease areas. Table of Contents: - Introduction to subcutaneous drug delivery - Biology of hyaluronan and hyaluronidases in the subcutaneous space - History of hyaluronidases and development of rHuPH20 - The ENHANZE platform: Clinical applications of a subcutaneous drug delivery technology - Application of EN

HANZE drug delivery technology: Development of currently marketed products [Publisher's text].

Special access authorizations may apply; please contact us for further information.